Darren R. Gitelman
YOU?
Author Swipe
View article: Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study
Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study Open
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symp…
View article: Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline
Baseline characteristics of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Successful enrollment of a diverse clinical trial cohort at risk for cognitive decline Open
INTRODUCTION The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial of two lifestyle interventions in 2111 older adults at increased risk for cognitive de…
View article: System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment
System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment Open
Promising therapeutic interventions that target the underlying pathophysiology are changing the landscape of Alzheimer's disease (AD) research. The AD care pathway must be transformed to meet the challenge of bringing these new therapies t…
View article: Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study Open
Objective: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. …
View article: The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition Open
INTRODUCTION The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is evaluating lifestyle interventions in older adults at risk for cognitive decline and dementia. Here we characterize the bas…
View article: EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT Open
There is an important unmet need for timely, noninvasive, low-burden diagnostic tools to aid in Alzheimer’s disease evaluation. The AAA-BBM2 (PrecivityAD2™) blood test combines plasma amyloid beta (AB)42/40 Ratio and phosphorylated-tau217/…
View article: EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT Open
There is an important unmet need for timely, noninvasive, low-burden diagnostic tools to aid in Alzheimer’s disease evaluation. The AAA-BBM2 (PrecivityAD2™) blood test combines plasma amyloid beta (AB)42/40 Ratio and phosphorylated-tau217/…
View article: IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY
IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY Open
Recent studies have shown that commercially available, high-performing blood biomarkers (BBMs) for Alzheimer’s disease (AD) pathology represent accurate, accessible, acceptable, and equitable tools to aid health care providers (HCPs) in th…
View article: AUTALIC: A Dataset for Anti-AUTistic Ableist Language In Context
AUTALIC: A Dataset for Anti-AUTistic Ableist Language In Context Open
As our understanding of autism and ableism continues to increase, so does our understanding of ableist language towards autistic people. Such language poses a significant challenge in NLP research due to its subtle and context-dependent na…
View article: Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI
Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI Open
Background A key focus of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is recruitment of unimpaired older individuals at risk for cognitive decline with heterogeneous characteristics (…
View article: Relationship between Arterial Transit Time and Framingham Risk Score in the U.S. POINTER lifestyle intervention trial
Relationship between Arterial Transit Time and Framingham Risk Score in the U.S. POINTER lifestyle intervention trial Open
Background The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a two‐year randomized controlled trial designed to evaluate the effects of lifestyle interventions on older adults aged 60‐79…
View article: Education, digital tools, and diagnostic support to increase PCP‐based cognitive testing in patients 65 years and older
Education, digital tools, and diagnostic support to increase PCP‐based cognitive testing in patients 65 years and older Open
In the United States, primary care clinicians (PCPs) typically diagnose and treat most patients who have or who may be developing neurocognitive disorders (NCDs). However, as many as two‐thirds of patients remain underdiagnosed, misdiagnos…
View article: LatAm‐FINGERS and U.S. POINTER: Design and Cohort Characteristics of Parallel Harmonized Trials of Multidomain Lifestyle Interventions Targeting Cognition
LatAm‐FINGERS and U.S. POINTER: Design and Cohort Characteristics of Parallel Harmonized Trials of Multidomain Lifestyle Interventions Targeting Cognition Open
Background Multidomain lifestyle interventions hold great promise world‐wide as interventions to slow cognitive aging, and delay and prevent Alzheimer’s Disease and Related Disorders (ADRD). To have the greatest reach, they must be tailore…
View article: Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI
Cohort heterogeneity and AD biomarkers in older adults without significant cognitive impairment: A comparison of U.S. POINTER and ADNI Open
Background A key focus of the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is recruitment of unimpaired older individuals at risk for cognitive decline with heterogeneous characteristics (…
View article: Background and Design of the U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER)
Background and Design of the U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Open
Background U.S. POINTER is a Phase 3, multicenter, randomized 2‐year clinical trial of two multidomain lifestyle interventions in 2111 older adults who are at increased risk of cognitive decline and dementia due sedentary lifestyle, poor d…
View article: The impact of art therapy on the relationships between individuals diagnosed with Alzheimer’s disease and their care partners
The impact of art therapy on the relationships between individuals diagnosed with Alzheimer’s disease and their care partners Open
Background Individuals with dementia have long reported negative social and psychological experiences. The current study employed a small group art therapy intervention; the intra‐ and inter‐personal impact was assessed through patient and…
View article: Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER)
Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER) Open
INTRODUCTION The U . S . study to pr o tect brain health through lifestyle inte rvention to r educe risk (U.S. POINTER) is conducted to confirm and expand the results of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairm…
View article: Choice of Inversion Time for Arterial Spin Labeling MRI in the U.S. POINTER Lifestyle Intervention Trial
Choice of Inversion Time for Arterial Spin Labeling MRI in the U.S. POINTER Lifestyle Intervention Trial Open
Background The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial to evaluate the effect of lifestyle interventions in older adults (60‐79 years). The POI…
View article: Optimizing quantification of MK6240 tau PET in unimpaired older adults
Optimizing quantification of MK6240 tau PET in unimpaired older adults Open
View article: U.S. POINTER: Lessons learned about delivery of a multi‐domain lifestyle intervention during the COVID‐19 pandemic
U.S. POINTER: Lessons learned about delivery of a multi‐domain lifestyle intervention during the COVID‐19 pandemic Open
Background U.S. POINTER is testing whether multidomain lifestyle interventions focused on physical exercise, nutrition, cognitive challenge, and risk factor management reduces risk of cognitive decline in a heterogeneous population of at‐r…
View article: Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial
Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial Open
Background The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial to evaluate the effect of lifestyle interventions in older adults (60‐79 years) who are …
View article: U.S. POINTER (USA)
U.S. POINTER (USA) Open
Background U.S. POINTER aims to test whether a multidomain lifestyle intervention focused on physical and cognitive activity, nutrition, and risk factor management reduces risk of cognitive decline in a heterogeneous population of older ad…
View article: A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson’s Disease
A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson’s Disease Open
Cognitive impairment is common in Parkinson’s disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition.
View article: Improving clinical cognitive testing: Report of the AAN Behavioral Neurology Section Workgroup
Improving clinical cognitive testing: Report of the AAN Behavioral Neurology Section Workgroup Open
OBJECTIVE: To evaluate the evidence basis of single-domain cognitive tests frequently used by behavioral neurologists in an effort to improve the quality of clinical cognitive assessment. METHODS: Behavioral Neurology Section members of th…
View article: Cognitive Impairment in Aging Physicians
Cognitive Impairment in Aging Physicians Open
Aging physicians are at a higher risk of cognitive impairment, undermining patient safety and unraveling physicians' careers. Neurologists, occupational health physicians, and psychiatrists will participate in both health system policy dec…
View article: Neural Connectivity in Syntactic Movement Processing
Neural Connectivity in Syntactic Movement Processing Open
Linguistic theory suggests non-canonical sentences subvert the dominant agent-verb-theme order in English via displacement of sentence constituents to argument (NP-movement) or non-argument positions (wh-movement). Both processes ha…
View article: Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database
Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database Open
Alzheimer disease (AD) represents a genetically heterogeneous entity. To elucidate neuropathologic features of autosomal dominant AD ([ADAD] due to PSEN1, APP, or PSEN2 mutations), we compared hallmark AD pathologic findings in 60 cases of…
View article: Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson’s Disease patients assessed using pseudo-continuous arterial spin labeling
Effects of acute levodopa challenge on resting cerebral blood flow in Parkinson’s Disease patients assessed using pseudo-continuous arterial spin labeling Open
Introduction. Levodopa is the gold-standard for treatment of Parkinson’s disease (PD) related motor symptoms. In this study, we used pseudo-continuous arterial spin labeling (pCASL) to quantify changes in cerebral blood flow (CBF) after ac…
View article: Reduced prefrontal activation during working and long‐term memory tasks and impaired patient‐reported cognition among cancer survivors postchemotherapy compared with healthy controls
Reduced prefrontal activation during working and long‐term memory tasks and impaired patient‐reported cognition among cancer survivors postchemotherapy compared with healthy controls Open
BACKGROUND Patients who receive adjuvant chemotherapy have reported cognitive impairments that may last for years after the completion of treatment. Working memory‐related and long‐term memory‐related changes in this population are not wel…
View article: Olfactory-visual integration facilitates perception of subthreshold negative emotion
Olfactory-visual integration facilitates perception of subthreshold negative emotion Open